| Enrolling By Invitation | Connectomic Guided DBS for Parkinson's Disease NCT06618157 | Duke University | N/A |
| Recruiting | Registry and Natural History of Epilepsy-Dyskinesia Syndromes NCT06967727 | Boston Children's Hospital | — |
| Recruiting | Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) NCT07023224 | Izmir Bakircay University | — |
| Recruiting | A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy- NCT06585605 | Boston Children's Hospital | — |
| Terminated | Open-Label Extension Study of ASTORIA NCT05516875 | Contera Pharma A/S | Phase 2 |
| Recruiting | Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia NCT05317390 | Massachusetts Eye and Ear Infirmary | N/A |
| Terminated | Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-bas NCT05116813 | Addex Pharma S.A. | Phase 2 / Phase 3 |
| Suspended | Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia NCT04912115 | PharmaTher Inc. | Phase 2 |
| Completed | Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia NCT05044572 | Riphah International University | N/A |
| Completed | Effects of Music Beat on Motor Function in Individuals At Risk for Psychotic Onset and Schizophrenia Patients NCT04929795 | Dr WANG Shumei | N/A |
| Terminated | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therap NCT04857359 | Addex Pharma S.A. | Phase 2 / Phase 3 |
| Terminated | Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Component NCT04377945 | Bukwang Pharmaceutical | Phase 2 |
| Unknown | Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophr NCT04553835 | Dr WANG Shumei | N/A |
| Completed | Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia NCT04351360 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Unknown | Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Indi NCT04086160 | Dr WANG Shumei | N/A |
| Completed | A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia NCT03956979 | Contera Pharma | Phase 2 |
| Unknown | A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease NCT04453995 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Terminated | Effect of the Visual Information Change in Functional Dystonia NCT03270189 | Fondation Ophtalmologique Adolphe de Rothschild | N/A |
| Suspended | An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease NCT03034538 | The Cooper Health System | Phase 4 |
| Terminated | Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia NCT02589340 | Oregon Health and Science University | Phase 1 |
| Completed | Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced D NCT01491529 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias NCT01491932 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias NCT01385592 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease NCT01474421 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in P NCT00986414 | Novartis | Phase 2 |
| Completed | Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects NCT00360568 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics NCT00888186 | Uppsala University | Phase 4 |
| Completed | Effects of Talampanel on Patients With Advanced Parkinson's Disease NCT00036296 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 / Phase 2 |
| Completed | Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) NCT00467597 | US Department of Veterans Affairs | — |
| Completed | ACP-103 to Treat Parkinson's Disease NCT00086294 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Levetiracetam Treatment of L-dopa Induced Dyskinesias NCT00076674 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parki NCT00363727 | GlaxoSmithKline | Phase 3 |
| Completed | Study of LY300164 for the Treatment of Parkinson's Disease NCT00004576 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |